Cachexia - Pipeline Insight, 2022

This “Cachexia- Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cachexia Understanding

Cachexia: Overview

Cachexia or wasting syndrome is a complicated metabolic syndrome related to underlying illness and characterized by muscle mass loss with or without fat mass loss that is often associated with anorexia, an inflammatory process, insulin resistance, and increased protein turnover. This specific ailment was described as a syndrome of irreversible muscle wasting, extreme weight loss and loss of body fat in the terminally ill patients in the late stages of serious diseases like cancer, HIV or AIDS, COPD, kidney disease, and congestive heart failure (CHF). Cachexia is characterized by a persistent increase in basal metabolic rate that is not compensated by increased caloric/protein intake. The common symptoms of cachexia include: Involuntary weight loss, muscle wasting, loss of appetite, or anorexia, reduced functional ability and swelling or edema. Clinically, cachexia manifests as asthenia; anorexia; early satiety; nausea; taste change; significant loss of body fat, muscle, and other components; anemia; and hormonal aberration. Cachexia is generally caused by "tumor factors", substances manufactured and secreted by a tumor, or by the "host response". Host response simply means the body's response to a tumor. The response of the immune system to cancer and other causes of cachexia is being studied to try and understand the underlying factors behind cachexia. Cachexia is dominated by catabolic metabolism. Cachexia is seen frequently with cancer but is also seen with diseases such as AIDS/HIV, heart failure, emphysema, and kidney failure. Cachexia is a significant factor in around one-fifth of deaths due to cancer. The aim of treatment in Cachexia is to stimulate "anabolic processes" (that is, muscle building) while inhibiting "catabolic processes" (the actions that result in the breakdown of muscle). There is no single medicine or treatment plan that has been shown to be effective for treating cachexia. Many factors contribute to its cause, so a treatment plan incorporating several types of therapy will most likely be necessary. Simply increasing the number of calories or changing the diet will not show results.

"Cachexia- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cachexia pipeline landscape is provided which includes the disease overview and Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.

Cachexia Emerging Drugs Chapters

This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cachexia Emerging Drugs

ACM 001: Actimed Therapeutics

ACM-001 (S-pindolol) - previously known as MT-102 - is a lead candidate of Actimed therapeutics and is chemically-related to a well-established beta-blocker for hypertension and angina (pindolol). S-pindolol (ACM-001) is an anabolic/catabolic transforming agent with a multifunctional effect on three key pharmacological targets relevant for cancer cachexia: β-1receptor antagonism that blocks catabolism, increased anabolism and muscle growth, through partial β2 receptor agonism, central 5-HT1A antagonism that can stimulate appetite and thereby improve overall patient outcomes as well as improving fatigue.This trio of anti-catabolic and pro-anabolic pharmacology makes S-pindolol (ACM-001) a unique candidate for development in cancer cachexia.

EOM613: EOM Pharmaceuticals

EOM613 is an investigational, first-in-class, dual-acting, broad-spectrum immunomodulator designed to provide both an anti-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect, when needed. EOM613 is designed to counteract the most severe inflammatory effects of viruses, such as cytokine storm or hyper immune response following infection with the novel coronavirus that causes COVID-19, autoimmune attacks that cause joint damage and pain associated with rheumatoid arthritis, and cytokine- and chemokine-related body-wasting syndromes such as cachexia.

Macimorelin: AEterna Zentaris

AEterna Zentaris is developing an orally administered Macimorelin (AEZS 130), a small-molecule, peptidomimetic growth hormone secretagogue receptor (GHSR1A) agonist (ghrelin analogue) for the treatment of cachexia associated with chronic disease such as AIDS and cancer in phase II clinical stage. Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand.

OC514: Oncocross

Oncocross is developing OC514, a drug-drug combination product containing 2 active pharmaceutical ingredients for cancer cachexia in Phase I stage of development.

NGM120: NGM Biopharmaceuticals

NGM120 is an antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling. NGM scientists have made several important discoveries related to GDF15, including identification of its cognate receptor, GFRAL. GFRAL is expressed in a specific region of the hindbrain, partially outside the blood brain barrier, and is believed to initiate signaling through multiple pathways, including the autonomic nervous system. NGM120 binds with high affinity to GFRAL to prevent the formation of the GDF15 co-receptor complex and its mediated signaling.

PF-06946860: Pfizer

Pfizer is developing a new drug PF-06946860 for the treatment of Cachexia. PF-06946860 is a biologic molecule which belongs to the class of appetite stimulants. The mechanism of action of the drug is that it acts like a Growth Factor Blocker. The product is currently in phase I stage of development.

Cachexia: Therapeutic Assessment

This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cachexia

There are approx. 25+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the most advanced stage, i.e. phase II include, Actimed Therapeutics.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cachexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.

Cachexia Report Insights

• Cachexia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cachexia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cachexia drugs?
• How many Cachexia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cachexia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Actimed Therapeutics
• Green Cross Wellbeing
• EOM Pharmaceuticals
• AEterna Zentaris
• GlaxoSmithKline
• Incyte Corporation
• Oncocross
• AVEO Oncology
• NGM Biopharmaceuticals
• Pfizer
• Extend Biosciences
• Energenesis Biomedica
• AAVogen
• ImmunoForge
• Immuneering Corporation
• CatalYm
• TMS Co. Ltd
• Endevica Bio
• Caelus Health
• Tvardi Therapeutics
• Faraday Pharmaceuticals

Key Products

• ACM 001
• GCBWB204
• EOM613
• Macimorelin
• GSK2881078
• Ruxolitinib
• OC514
• AV-380
• NGM120
• PF 06946860
• EXT418
• ENERGI-F704
• AVGN7
• PF-1801
• Research Programme (Cancer Cachexia)
• CTL-002
• TMS-008
• TCMCB07
• CH-0701
• TTI 101

This product will be delivered within 1-3 business days.